Oncol-话题@MedSci

#Oncol#

2384篇内容 | 2465人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1866713, encodeId=0a341866e1322, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：白消安 vs 全身放疗联合环磷酰胺治疗成人急性B淋巴细胞白血病, objectType=article, longId=739393, objectId=dc53e393931b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc53e393931b, replyNumber=0, likeNumber=86, createdTime=2022-11-09, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc53e393931b, moduleTitle=J Clin Oncol：白消安 vs 全身放疗联合环磷酰胺治疗成人急性B淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc53e393931b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866565, encodeId=e240186656561, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Oncologist: HER2阳性胃癌既往曲妥珠单抗治疗进展后继续曲妥珠单抗联合伊立替康治疗并不能增加生存获益, objectType=article, longId=301447, objectId=d0c230144eb9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0c230144eb9, replyNumber=0, likeNumber=75, createdTime=2022-11-01, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0c230144eb9, moduleTitle=Oncologist: HER2阳性胃癌既往曲妥珠单抗治疗进展后继续曲妥珠单抗联合伊立替康治疗并不能增加生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0c230144eb9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866531, encodeId=a59a1866531c5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：乳腺癌患者晚期复发后的死亡率, objectType=article, longId=299757, objectId=5596299e57e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5596299e57e1, replyNumber=0, likeNumber=81, createdTime=2022-07-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5596299e57e1, moduleTitle=J Clin Oncol：乳腺癌患者晚期复发后的死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5596299e57e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866654, encodeId=b70f18666545f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：卡培他滨加用奥沙利铂可作为II-III期结直肠癌的替代辅助治疗, objectType=article, longId=731074, objectId=f8d8e3107483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8d8e3107483, replyNumber=0, likeNumber=139, createdTime=2022-10-31, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8d8e3107483, moduleTitle=J Clin Oncol：卡培他滨加用奥沙利铂可作为II-III期结直肠癌的替代辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8d8e3107483)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866680, encodeId=e416186668039, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：乐伐替尼联合经动脉化疗栓塞可显著改善晚期肝癌患者预后, objectType=article, longId=734441, objectId=ecbfe3444119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ecbfe3444119, replyNumber=0, likeNumber=79, createdTime=2022-09-13, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ecbfe3444119, moduleTitle=J Clin Oncol：乐伐替尼联合经动脉化疗栓塞可显著改善晚期肝癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ecbfe3444119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866504, encodeId=5b8d1866504e5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Target Oncol:FLAURA中国研究表明一线奥希替尼治疗较吉非替尼改善中国人群EGFR突变NSCLC患者的预后, objectType=article, longId=295592, objectId=e4e3295592aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4e3295592aa, replyNumber=0, likeNumber=83, createdTime=2022-12-13, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4e3295592aa, moduleTitle=Target Oncol:FLAURA中国研究表明一线奥希替尼治疗较吉非替尼改善中国人群EGFR突变NSCLC患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4e3295592aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866534, encodeId=3ca318665343b, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Hematol Oncol：癌症患者接种SARS-COV2疫苗后的血清学反应, objectType=article, longId=299887, objectId=481729988e87, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=481729988e87, replyNumber=0, likeNumber=72, createdTime=2023-01-25, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=481729988e87, moduleTitle=J Hematol Oncol：癌症患者接种SARS-COV2疫苗后的血清学反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=481729988e87)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866556, encodeId=670e1866556d5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：癌症患儿、医生、监护人报告的癌症治疗的不良反应的差异性, objectType=article, longId=301179, objectId=fa7d3011e93f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa7d3011e93f, replyNumber=0, likeNumber=85, createdTime=2022-04-18, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa7d3011e93f, moduleTitle=J Clin Oncol：癌症患儿、医生、监护人报告的癌症治疗的不良反应的差异性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa7d3011e93f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866612, encodeId=ab1718666120a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle= J Hematol Oncol：直接口服抗凝剂与低分子量肝素治疗癌症相关静脉血栓栓塞——2022 年更新的随机对照试验的系统评价和荟萃分析, objectType=article, longId=727694, objectId=17eae2769469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17eae2769469, replyNumber=0, likeNumber=53, createdTime=2023-01-25, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17eae2769469, moduleTitle= J Hematol Oncol：直接口服抗凝剂与低分子量肝素治疗癌症相关静脉血栓栓塞——2022 年更新的随机对照试验的系统评价和荟萃分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17eae2769469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866547, encodeId=f79b186654e9b, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：国内多中心III期研究表明局部进展期直肠癌术前短程放疗+化疗（TNT）是可行的治疗方案, objectType=article, longId=300860, objectId=e92c300860d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e92c300860d9, replyNumber=0, likeNumber=178, createdTime=2022-04-14, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e92c300860d9, moduleTitle=J Clin Oncol：国内多中心III期研究表明局部进展期直肠癌术前短程放疗+化疗（TNT）是可行的治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e92c300860d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866651, encodeId=10761866651a5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：伊匹单抗 vs FOLFOX联合纳武单抗和曲妥珠单抗治疗ERBB2阳性胃食管腺癌, objectType=article, longId=730595, objectId=f470e305957c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f470e305957c, replyNumber=0, likeNumber=89, createdTime=2023-04-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f470e305957c, moduleTitle=JAMA Oncol：伊匹单抗 vs FOLFOX联合纳武单抗和曲妥珠单抗治疗ERBB2阳性胃食管腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f470e305957c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866686, encodeId=e4b8186668668, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：瑞派替尼 vs 舒尼替尼后线治疗晚期胃肠道间质瘤, objectType=article, longId=735738, objectId=bcb3e35738dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bcb3e35738dd, replyNumber=0, likeNumber=72, createdTime=2022-11-15, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bcb3e35738dd, moduleTitle=J Clin Oncol：瑞派替尼 vs 舒尼替尼后线治疗晚期胃肠道间质瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bcb3e35738dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866432, encodeId=1ca0186643272, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet oncol：替莫唑胺辅助治疗可改善放疗后的间变性胶质细胞瘤患者的生存预后！, objectType=article, longId=293001, objectId=3e2e29300136, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e2e29300136, replyNumber=0, likeNumber=67, createdTime=2022-06-24, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e2e29300136, moduleTitle=Lancet oncol：替莫唑胺辅助治疗可改善放疗后的间变性胶质细胞瘤患者的生存预后！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e2e29300136)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866609, encodeId=58d91866609fd, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Thorac Oncol: 国产PD-1抑制剂信迪利单抗新辅助治疗非小细胞肺癌（NSCLC）的三年随访生存结果, objectType=article, longId=727595, objectId=086be27595c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=086be27595c5, replyNumber=0, likeNumber=69, createdTime=2022-10-14, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=086be27595c5, moduleTitle=J Thorac Oncol: 国产PD-1抑制剂信迪利单抗新辅助治疗非小细胞肺癌（NSCLC）的三年随访生存结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=086be27595c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866525, encodeId=ec6b1866525a3, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效, objectType=article, longId=299451, objectId=fc31299451e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc31299451e9, replyNumber=0, likeNumber=82, createdTime=2022-08-02, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc31299451e9, moduleTitle=Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc31299451e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866476, encodeId=8c5518664e61c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：依鲁替尼-利妥昔单抗诱导治疗可减少套细胞淋巴瘤的化疗疗程, objectType=article, longId=295064, objectId=3d5529506462, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d5529506462, replyNumber=0, likeNumber=106, createdTime=2022-10-01, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d5529506462, moduleTitle=Lancet Oncol：依鲁替尼-利妥昔单抗诱导治疗可减少套细胞淋巴瘤的化疗疗程, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d5529506462)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866464, encodeId=bbc91866464fa, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究, objectType=article, longId=294454, objectId=3f302944546a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f302944546a, replyNumber=0, likeNumber=86, createdTime=2022-04-09, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f302944546a, moduleTitle=J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f302944546a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866685, encodeId=c0b61866685c5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：利妥昔单抗联合来那度胺或化疗治疗滤泡性淋巴瘤的长期预后, objectType=article, longId=735726, objectId=b3d4e3572648, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3d4e3572648, replyNumber=0, likeNumber=90, createdTime=2022-09-27, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3d4e3572648, moduleTitle=J Clin Oncol：利妥昔单抗联合来那度胺或化疗治疗滤泡性淋巴瘤的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3d4e3572648)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866701, encodeId=69191866e0161, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌的患者报告的预后, objectType=article, longId=738674, objectId=c94ce38674b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c94ce38674b5, replyNumber=0, likeNumber=104, createdTime=2023-04-15, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c94ce38674b5, moduleTitle=Lancet Oncol：奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌的患者报告的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c94ce38674b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866436, encodeId=c7c1186643668, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：3期随机试验 | 序贯放化疗 vs 同步放化疗用作早期宫颈癌术后辅助治疗的疗效, objectType=article, longId=293024, objectId=52cc2930249f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52cc2930249f, replyNumber=0, likeNumber=68, createdTime=2022-07-05, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52cc2930249f, moduleTitle=JAMA Oncol：3期随机试验 | 序贯放化疗 vs 同步放化疗用作早期宫颈癌术后辅助治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52cc2930249f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Oncol

2020-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：白消安 vs 全身放疗联合环磷酰胺治疗成人急性B淋巴细胞白血病

2022-11-09

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Oncologist: HER2阳性胃癌既往曲妥珠单抗治疗进展后继续曲妥珠单抗联合伊立替康治疗并不能增加生存获益

2022-11-01

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：乳腺癌患者晚期复发后的死亡率

2022-07-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：卡培他滨加用奥沙利铂可作为II-III期结直肠癌的替代辅助治疗

2022-10-31

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：乐伐替尼联合经动脉化疗栓塞可显著改善晚期肝癌患者预后

2022-09-13

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Target Oncol:FLAURA中国研究表明一线奥希替尼治疗较吉非替尼改善中国人群EGFR突变NSCLC患者的预后

2022-12-13

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Hematol Oncol：癌症患者接种SARS-COV2疫苗后的血清学反应

2023-01-25

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：癌症患儿、医生、监护人报告的癌症治疗的不良反应的差异性

2022-04-18

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Hematol Oncol：直接口服抗凝剂与低分子量肝素治疗癌症相关静脉血栓栓塞——2022 年更新的随机对照试验的系统评价和荟萃分析

2023-01-25

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：国内多中心III期研究表明局部进展期直肠癌术前短程放疗+化疗（TNT）是可行的治疗方案

2022-04-14

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：伊匹单抗 vs FOLFOX联合纳武单抗和曲妥珠单抗治疗ERBB2阳性胃食管腺癌

2023-04-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：瑞派替尼 vs 舒尼替尼后线治疗晚期胃肠道间质瘤

2022-11-15

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet oncol：替莫唑胺辅助治疗可改善放疗后的间变性胶质细胞瘤患者的生存预后！

2022-06-24

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Thorac Oncol: 国产PD-1抑制剂信迪利单抗新辅助治疗非小细胞肺癌（NSCLC）的三年随访生存结果

2022-10-14

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效

2022-08-02

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：依鲁替尼-利妥昔单抗诱导治疗可减少套细胞淋巴瘤的化疗疗程

2022-10-01

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究

2022-04-09

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：利妥昔单抗联合来那度胺或化疗治疗滤泡性淋巴瘤的长期预后

2022-09-27

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌的患者报告的预后

2023-04-15

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：3期随机试验 | 序贯放化疗 vs 同步放化疗用作早期宫颈癌术后辅助治疗的疗效

2022-07-05

科室
- - 订阅+
  - 更多科室
工具
服务